17 Dec 2020
Share:
More and more revolutionary mind-altering medicines and treatments based on active ingredients previously spurned as street drugs, such as ketamine and psilocybin (magic mushrooms), are gaining acceptance with regulators. Clinical trials show psychedelics have huge potential to help people with treatment resistant mental illnesses including depression, addiction, anxiety and inflammation. So, with the launch of its first investment fund, will the psychedelic healthcare sector run at the heels of the medicinal cannabis industry and enable Europe to become the new hub of a burgeoning market sector?
The UK's first investment fund dedicated solely to psychedelic healthcare has launched.